Sounds interesting. I found this spam on this stock at the SIRI board today. I did some cursory checking on the claims and they seem to be right on. Bought a few K because it looks like a low risk investment at these prices. I like the fact that the company has an currrent stock buybback program.
For whatever is worth:
TWO DAYS LEFT THIS MONTH....BIG PRODUCT ANNOUNCEMENT COMING UP
PROFITABLE...STRONG BALANCE SHEET...ONGOING STOCK BUYBACK PROGRAM...TRADING AT 0.5 P/S TARGET: $3++ by YEAR END
During the 4Q CC this month, the company said that it will announce in late September the introduction of its patent-pending DX2, high-margin, new light-therapy pain management product. Expect a 10 - 20% pop when the announcement is made.
Dynatronics (Nasdaq: DYNT) recently reported another profitable year for FY 2006. 2007 is looking like it will be a strong year for DYNT. DYNT's CEO predicted at least 10% revenue growth and a substantial increase in net income.....1Q 2007 will be reported in about 6 weeks:
From the earnings release and CC:
-- DYNT was profitable again. However, revenues and net income were slightly lower than the previous year because of a substantial increase in R&D activities and the effort needed to launch a number of products late in 2006.
-- The effect of the new products on revenues and net income will start showing up in Q1 2007 to be reported in early November.
-- The backlog for the new Dynatronic X3 light therapy unit released during August 2006 (1Q 2007) has been fulfilled. Expect added revenues and net income in 1Q 2007 resulting from it.
-- DYNT will lower R&D expenses by about 5c/share in 2007 from 2006's record levels.
***** DYNT WILL RELEASE THE NEW REVOLUTIONARY PATENT-PENDING DX2 PAIN MANAGEMENT DEVICE THIS MONTH ****.....
-- The company believes the stock is undervalued and has triggered its stock-buyback program. About 50K shares have recently been purchased. DYNT has cash authorized to buy 250K more shares. the company activates its buyback program when the stock dips under $1.3.
-- A new major product will be launched in November 2006. This product works with the new DX2 device.
-- Based on the new product launches and reduced R&D costs, DYNT expects at least a 10% revenue growth and substatially higher net income. I believe net income will range from 10 - 15c/share in 2007.
SELECTED COMPANY COMMENTS FROM 2006 EARNINGS RELEASE and CC
..."New products introduced during the past year include the Dynatron 702, a stand-alone light therapy device, as well as the new DX9 combination traction and light therapy system. The DX9 system combines the benefits of infrared light therapy using the Dynatron 702 with decompression therapy using the Company's TX900 Traction device. This unique combination of modalities has been reported to be highly effective in the treatment of back pain..."
"Looking ahead to fiscal 2007, we are pleased to have begun the year with the July 2006 introduction of the new Dynatron X3 infrared light therapy device," said Larry K. Beardall, executive vice president for sales and marketing. "In addition, we plan to introduce the much anticipated DX2 proprietary traction device later this month. The DX2 incorporates patent-pending technology and will utilize the new T4 treatment table which is specially designed for traction and decompression therapies. The T4 treatment table is scheduled for introduction in November 2006."
The new DX2 is currently undergoing clinical beta testing and has been previewed at several national trade shows. "Interest in the DX2 from practitioners at the national trade shows has been substantial," reported Beardall. "While the development effort has taken longer than anticipated, we believe this innovative approach to treating back pain will prove to be a great benefit to patients."
OTHER DYNT HIGHLIGHTS:
* DYNT IS THE LEADER IN LIGHT THERAPY FOR PAIN MANAGEMENT
* FDA APPROVED and PATENTED PRODUCTS
* NEW PRODUCTS WILL YIELD SUBSTANTIAL GAINS IN REVENUE AND NET INCOME STARTING with 1Q 2007.....
* PROFITABLE AND TRADING AT 0.5 P/S
* STRONG BALANCE SHEET
For whatever is worth:
TWO DAYS LEFT THIS MONTH....BIG PRODUCT ANNOUNCEMENT COMING UP
PROFITABLE...STRONG BALANCE SHEET...ONGOING STOCK BUYBACK PROGRAM...TRADING AT 0.5 P/S TARGET: $3++ by YEAR END
During the 4Q CC this month, the company said that it will announce in late September the introduction of its patent-pending DX2, high-margin, new light-therapy pain management product. Expect a 10 - 20% pop when the announcement is made.
Dynatronics (Nasdaq: DYNT) recently reported another profitable year for FY 2006. 2007 is looking like it will be a strong year for DYNT. DYNT's CEO predicted at least 10% revenue growth and a substantial increase in net income.....1Q 2007 will be reported in about 6 weeks:
From the earnings release and CC:
-- DYNT was profitable again. However, revenues and net income were slightly lower than the previous year because of a substantial increase in R&D activities and the effort needed to launch a number of products late in 2006.
-- The effect of the new products on revenues and net income will start showing up in Q1 2007 to be reported in early November.
-- The backlog for the new Dynatronic X3 light therapy unit released during August 2006 (1Q 2007) has been fulfilled. Expect added revenues and net income in 1Q 2007 resulting from it.
-- DYNT will lower R&D expenses by about 5c/share in 2007 from 2006's record levels.
***** DYNT WILL RELEASE THE NEW REVOLUTIONARY PATENT-PENDING DX2 PAIN MANAGEMENT DEVICE THIS MONTH ****.....
-- The company believes the stock is undervalued and has triggered its stock-buyback program. About 50K shares have recently been purchased. DYNT has cash authorized to buy 250K more shares. the company activates its buyback program when the stock dips under $1.3.
-- A new major product will be launched in November 2006. This product works with the new DX2 device.
-- Based on the new product launches and reduced R&D costs, DYNT expects at least a 10% revenue growth and substatially higher net income. I believe net income will range from 10 - 15c/share in 2007.
SELECTED COMPANY COMMENTS FROM 2006 EARNINGS RELEASE and CC
..."New products introduced during the past year include the Dynatron 702, a stand-alone light therapy device, as well as the new DX9 combination traction and light therapy system. The DX9 system combines the benefits of infrared light therapy using the Dynatron 702 with decompression therapy using the Company's TX900 Traction device. This unique combination of modalities has been reported to be highly effective in the treatment of back pain..."
"Looking ahead to fiscal 2007, we are pleased to have begun the year with the July 2006 introduction of the new Dynatron X3 infrared light therapy device," said Larry K. Beardall, executive vice president for sales and marketing. "In addition, we plan to introduce the much anticipated DX2 proprietary traction device later this month. The DX2 incorporates patent-pending technology and will utilize the new T4 treatment table which is specially designed for traction and decompression therapies. The T4 treatment table is scheduled for introduction in November 2006."
The new DX2 is currently undergoing clinical beta testing and has been previewed at several national trade shows. "Interest in the DX2 from practitioners at the national trade shows has been substantial," reported Beardall. "While the development effort has taken longer than anticipated, we believe this innovative approach to treating back pain will prove to be a great benefit to patients."
OTHER DYNT HIGHLIGHTS:
* DYNT IS THE LEADER IN LIGHT THERAPY FOR PAIN MANAGEMENT
* FDA APPROVED and PATENTED PRODUCTS
* NEW PRODUCTS WILL YIELD SUBSTANTIAL GAINS IN REVENUE AND NET INCOME STARTING with 1Q 2007.....
* PROFITABLE AND TRADING AT 0.5 P/S
* STRONG BALANCE SHEET
